Entera Bio (ENTX) Net Cash Flow Growth (3y) (2024 - 2026)
Entera Bio (ENTX) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
- |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
- |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
- |
| 10 |
Entera Bio |
56.59 Mn |
52.45 Mn |
- |
-22.25% |
| Date | Value |
|---|
| Mar 31, 2026 |
-22.25% |
| Dec 31, 2025 |
5.75% |
| Sep 30, 2025 |
7.78% |
| Jun 30, 2025 |
15.47% |
| Mar 31, 2025 |
64.81% |
| Dec 31, 2024 |
39.22% |
| Sep 30, 2024 |
-87.25% |
| Jun 30, 2024 |
-26.23% |
| Mar 31, 2024 |
-30.75% |
